Library / Peptides / Cognitive & Neuro / P21
No human data · Grade D

P21

P21 (CNTF-Derived Peptide)
Evidence
No Human Data
Route
Subcutaneous injection or Intranasal
Frequency
Once daily
Category
Cognitive & Neuro
TL;DR
P21 is a small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF). It was designed to mimic CNTF's neurotrophic effects while being small enough to cross the blood-brain barrier.
Part 01 · How it works

Mechanism.

P21 is a small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF). It was designed to mimic CNTF's neurotrophic effects while being small enough to cross the blood-brain barrier. Research in animal models of Alzheimer's disease has shown P21 can enhance neurogenesis, reduce neurodegeneration, and improve cognitive function. No human clinical trials have been published.

P21 is like a concentrated extract of a brain growth signal. The full signal (CNTF) is too large to get through the brain's security checkpoint (blood-brain barrier), so scientists designed a miniature version that carries the same message -- 'grow and repair neurons' -- but is small enough to slip through.

Mechanism · technical
P21 is an 11-mer peptide that acts as a CNTF mimetic, binding to the CNTF receptor complex (CNTFRalpha/LIFRbeta/gp130) to activate downstream JAK/STAT and PI3K/Akt signaling pathways. This stimulates dentate gyrus neurogenesis (the birth of new neurons in the hippocampus) and enhances synaptic plasticity. In Alzheimer's models, P21 has been shown to reduce tau hyperphosphorylation and neurofibrillary tangle-like pathology through inhibition of GSK-3beta.
Part 02 · Dosing & administration

How it's taken.

Values below describe how P21 has been administered in published trials and labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Standard dose
500-1000 mcg
Subcutaneous injection or Intranasal · Once daily
Duration
4-6 weeks typical cycle

Small peptide derived from CNTF (ciliary neurotrophic factor). Promotes neurogenesis in animal models. No human clinical trials. Research compound only.

Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator
Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Reported side effects
No human safety data exists. Animal studies have not reported significant adverse effects. Theoretical concerns include uncontrolled cell proliferation given its neurogenesis-promoting properties. The absence of human pharmacokinetic and toxicology data means the side effect profile is essentially unknown.
Absolute · do not use
×
Pregnancy or breastfeeding
×
Children under 18
×
Known hypersensitivity to P21 peptide or any component
×
Active seizure disorders (neurotrophin modulation may affect seizure threshold)
×
Intracranial tumors
Interactions
Antidepressants (SSRIs, SNRIs)
P21 enhances neurotrophin signaling (BDNF/CNTF pathway); may have additive neurotrophic effects with antidepressants
Minor
Anticonvulsants
Neurotrophic peptides may alter seizure threshold; monitor seizure frequency
Moderate
Cholinesterase inhibitors
Additive neurotrophic/neuroprotective effects; theoretical benefit but monitor for cholinergic side effects
Minor
Labs to monitor
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver and kidney function
CBC with Differential
Baseline and every 3 months
General safety monitoring
BDNF Level (optional, research)
Baseline (optional, research context)
P21 may modulate neurotrophic factor signaling
Part 04 · Research log

Every study we cite.

Each study with its published finding and a plain-language note on limitations or funding.

01
2013
0
P21, a CNTF-derived peptide, promotes neurogenesis
P21 increased hippocampal neurogenesis and improved learning/memory in aged rats
Preclinical; no human data
PMID 23764294 ↗
02
2014
0
P21 prevents neurodegeneration in Alzheimer model
P21 reduced tau pathology and neuroinflammation in AD transgenic mice
Preclinical; same research group
PMID 25236584 ↗
Part 05 · Cost & access

Where you can get it.

Regulatory status
P21 is not FDA-approved for any indication. It is available as a research chemical. No regulatory body has approved it for human therapeutic use. It exists in a legal grey area similar to many research peptides.
The Peptide Column takes no affiliate commission from any source.
Part 06 · Your appointment

Questions to bring.

01
What is the current state of human evidence for P21?
02
Are there established safety profiles for this peptide in humans?
03
What are the risks of using a neurogenesis-promoting compound without clinical trial data?
04
Are there better-studied alternatives for cognitive support?